Shandong Bailong Chuangyuan Bio-Tech Co. Ltd.
Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. engages in the production and sale of food and feed additives in China and internationally. The company offers dietary fibers, including polydextrose and resistant dextrin; prebiotics, such as fructo-oligosaccharide, isomalto-oligosaccharide, galacto-oligosaccharide, and xylo-oligosaccharide. It also provides starch sugars comprising allulose, maltit… Read more
Shandong Bailong Chuangyuan Bio-Tech Co. Ltd. (605016) - Total Assets
Latest total assets as of September 2025: CN¥2.58 Billion CNY
Based on the latest financial reports, Shandong Bailong Chuangyuan Bio-Tech Co. Ltd. (605016) holds total assets worth CN¥2.58 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Shandong Bailong Chuangyuan Bio-Tech Co. Ltd. - Total Assets Trend (2016–2024)
This chart illustrates how Shandong Bailong Chuangyuan Bio-Tech Co. Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Shandong Bailong Chuangyuan Bio-Tech Co. Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
Shandong Bailong Chuangyuan Bio-Tech Co. Ltd.'s total assets of CN¥2.58 Billion consist of 44.8% current assets and 55.2% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 14.3% |
| Accounts Receivable | CN¥240.90 Million | 12.0% |
| Inventory | CN¥186.83 Million | 9.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥17.58 Million | 0.9% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Shandong Bailong Chuangyuan Bio-Tech Co. Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shandong Bailong Chuangyuan Bio-Tech Co. Ltd.'s current assets represent 44.8% of total assets in 2024, a decrease from 50.1% in 2016.
- Cash Position: Cash and equivalents constituted 14.3% of total assets in 2024, down from 26.4% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 2.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 12.0% of total assets.
Shandong Bailong Chuangyuan Bio-Tech Co. Ltd. Competitors by Total Assets
Key competitors of Shandong Bailong Chuangyuan Bio-Tech Co. Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
General Mills Inc
NYSE:GIS
|
USA | $32.55 Billion |
|
Maniker F & G Co. Ltd
KQ:195500
|
Korea | ₩123.42 Billion |
|
Xiwang Foodstuffs Co Ltd
SHE:000639
|
China | CN¥6.08 Billion |
|
Nanfang Black Sesame Group Co Ltd
SHE:000716
|
China | CN¥4.57 Billion |
|
CNFC Overseas Fishery Co Ltd
SHE:000798
|
China | CN¥5.88 Billion |
|
Henan Shuanghui Investment & Development Co Ltd
SHE:000895
|
China | CN¥40.64 Billion |
|
Xinjiang Chalkis Co Ltd
SHE:000972
|
China | CN¥1.25 Billion |
|
Daehan Flour Mills Co Ltd
KO:001130
|
Korea | ₩1.61 Trillion |
Shandong Bailong Chuangyuan Bio-Tech Co. Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Shandong Bailong Chuangyuan Bio-Tech Co. Ltd. generates 0.57x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Shandong Bailong Chuangyuan Bio-Tech Co. Ltd. generates $ 12.20 in net profit.
Shandong Bailong Chuangyuan Bio-Tech Co. Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.21 | 2.84 | 2.76 |
| Quick Ratio | 1.76 | 2.32 | 2.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥706.99 Million | CN¥ 555.21 Million | CN¥ 238.59 Million |
Shandong Bailong Chuangyuan Bio-Tech Co. Ltd. - Advanced Valuation Insights
This section examines the relationship between Shandong Bailong Chuangyuan Bio-Tech Co. Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.53 |
| Latest Market Cap to Assets Ratio | 0.28 |
| Asset Growth Rate (YoY) | 14.8% |
| Total Assets | CN¥2.01 Billion |
| Market Capitalization | $565.26 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shandong Bailong Chuangyuan Bio-Tech Co. Ltd.'s assets below their book value (0.28 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Shandong Bailong Chuangyuan Bio-Tech Co. Ltd.'s assets grew by 14.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Shandong Bailong Chuangyuan Bio-Tech Co. Ltd. (2016–2024)
The table below shows the annual total assets of Shandong Bailong Chuangyuan Bio-Tech Co. Ltd. from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.01 Billion | +14.78% |
| 2023-12-31 | CN¥1.75 Billion | +19.17% |
| 2022-12-31 | CN¥1.47 Billion | +14.77% |
| 2021-12-31 | CN¥1.28 Billion | +53.41% |
| 2020-12-31 | CN¥836.00 Million | +10.82% |
| 2019-12-31 | CN¥754.35 Million | +23.70% |
| 2018-12-31 | CN¥609.80 Million | -2.55% |
| 2017-12-31 | CN¥625.78 Million | -0.95% |
| 2016-12-31 | CN¥631.82 Million | -- |